





DON'T GUESS. SEE. Press Release

Michael J. Dormer, former Head of Johnson & Johnson Medical Devices & Diagnostics, named Chairman of the Board of Directors of EOS imaging

<u>Paris, 5 December 2012</u> - EOS imaging (NYSE Euronext, FR0011191766 – EOSI), the pioneer in 2D/3D orthopedic medical imaging, announced that it has appointed prominent orthopedic and medical device industry leader Michael J. Dormer as Chairman of the Board of Directors. Mr. Dormer, who joined the EOS Board earlier this year, will leverage his over 30 years of knowledge and expertise to guide the company as it continues to execute its growth strategy throughout the U.S., Europe and Asia.

"The EOS system is a groundbreaking technology, enabling physicians to capture 3D musculoskeletal images and obtain necessary clinical parameters with remarkably low radiation dose. I believe it has the potential to set a new standard for advanced orthopedic care, and I look forward to leading the Board and working with management to drive the continued growth of the Company as it introduces the EOS system to medical centers throughout the world," said Mr. Dormer.

Mr. Dormer has spent much of his career at Johnson & Johnson, the world's largest and most diverse medical devices and diagnostics company. In 1992, he joined DePuy Inc., a global leader in orthopedic implants, as President and led the company through its IPO in 1996 and its subsequent acquisition by Johnson & Johnson. Mr. Dormer then returned to Johnson & Johnson, most recently serving as the Chairman of the Medical Devices and Diagnostics division. Mr. Dormer has also served on the Executive Committee of the medical device industry group AdvaMed.

Marie Meynadier, CEO of EOS imaging, said, "Since he joined the Board earlier this year, we have already benefitted from Michael's strategic guidance, and we welcome him in his expanded role as Chairman. Michael's broad experience in the medical device industry, which includes significant knowledge of the orthopedic market, will be valuable as we continue to drive adoption of the EOS imaging system. He also has strong international experience and industry contacts, which we will leverage as we accelerate our growth in Asia and the U.S."

EOS imaging manufacturers the EOS® system, the first and only full body, low dose 2D/3D imaging technology available for orthopedic care. For more information, please visit www.eos-imaging.com.

About EOS imaging:


The EOS imaging group designs, develops and markets EOS®, a revolutionary and patented medical imaging system, based on technology that enabled George Charpak to win the Nobel Prize for Physics. The Group has obtained authorization to market the system in 30 countries, including the United States (FDA), Canada, Australia and the European Union (EU). Thanks to an installed base of 51 sites and more than 250,000 imaging sessions, EOS® benefits from worldwide recognition and established credibility within the medical community. The Group currently employs 57 people, including an R&D team of 21 engineers, and recorded consolidated revenue of €6.94 million in 2011. The Group's head office is based in Paris, with a subsidiary in the United States in Cambridge (Massachusetts), as well as in Montreal (Canada) and Germany. For further information, please go to: www.eos-imaging.com.

EOS imaging is listed on Compartment C of the NYSE Euronext Paris ISIN: FR0011191766 – Ticker: EOSI



Next press release: 2012 annual revenue on 21 January 2013 (after market).







DON'T GUESS. SEE. Press Release

Contacts:

Anne Renevot CFO

Tel.: +33 (0)1 55 25 61 24 investors@eos-imaging.com

The Ruth Group (US)

Press Relations - Lisa Cook Ph: 646-536-7012 lcook@theruthgroup.com NewCap.

Financial communication and investor relations
Sophie Boulila / Pierre Laurent
Tel.: +33 (0)1 44 71 94 91 – eosimaging@newcap.fr

ALIZE RP (Europe)

Press Relations
Caroline Carmagnol
Tel: +33 (0)1 42 68 86 43 / +33 (0)6 64 18 99 59
caroline@alizerp.com